argenx, a biopharmaceutical company, continues to make significant strides in its growth outlook. TD Cowen and Deutsche Bank have reiterated buy ratings on the company's stock, and the company achieved its first annual profitability in 2025 with net product sales rising a whopping 90% to $4.2 billion. The company also showed positive results from its VYVGART Phase 3 results and has announced some promising topline results. However, Argenx has discontinued the Phase 3 UplighTED trials of efgartigimod SC in thyroid eye disease. The CEO of Argenx is also stepping down to be replaced by the operating chief Karen Massey. There has been a leadership transition for the company, which generated mixed opinions from analysts on the stock. There is confidence in the VYVGART from Artisan Mid Cap Fund, and the FDA has accepted a supplemental biologics license application with priority review for VYVGART. While positive outcomes are shaping up from various studies, Argenx has discontinued certain trials due to setbacks in thyroid eye disease.
argenx News Analytics from Tue, 01 Jul 2025 07:00:00 GMT to Fri, 13 Mar 2026 14:47:09 GMT -
Rating 7
- Innovation 6
- Information 8
- Rumor 2
